Join us at the 2025 Society of Surgical Oncology (SSO) meeting
March 27-29, 2025 | Tampa, FL
We invite you to connect with us at SSO 2025 to learn how Haystack MRD can help guide treatment decisions with confidence. From the perioperative setting to recurrence surveillance, Haystack MRD tracks ctDNA across the treatment management journey—empowering oncologists to make informed, timely treatment decisions.
Visit us at the Quest Diagnostics booth (E9)
Stop by our booth to explore how Haystack MRD provides deep molecular insights that can help assess treatment response and inform clinical decision-making. Our team will be available to discuss the latest clinical evidence and answer your questions.
Attend the talk
Detecting the unseen: How Haystack MRD™ can help guide treatment decisions with more confidence
Presented by:
Thomas Slavin, MD MBA FACMGG DABMD
Chief Clinical Officer of Molecular Oncology and Medical Director of Haystack Oncology at Quest Diagnostics
Date: Thursday, March 27
Time: 1:05 – 1:25 PM
Talk overview:
• Understand how MRD testing can help assess treatment response and guide clinical decision-making
• Learn the value of ultrasensitive ctDNA detection in perioperative treatment management
• Explore the clinical evidence of ultrasensitive MRD testing to help shape treatment paradigms
We look forward to meeting you in Tampa and discussing how Haystack MRD can support your surgical oncology practice.
About Haystack MRD
Next-generation ctDNA detection with exceptional sensitivity and specificity for precise MRD reporting
Haystack MRD is a tumor-informed blood-based ctDNA detection test for measurement of residual disease in solid tumor settings. Exceptional sensitivity and specificity translate to better MRD detection for greater confidence when making key clinical decisions.
